JPXマーク
ホーム 市場調査レポートについて 医薬品 蛋白尿治療薬の世界市場
表紙：蛋白尿治療薬の世界市場

蛋白尿治療薬の世界市場

Proteinuria Therapeutics
発行
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
発行日
ページ情報
英文 199 Pages
納期
即日から翌営業日
商品コード
1551665
  • 適宜更新あり 本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 翻訳ツール提供対象 PDF対応AI翻訳ツールの無料貸し出しサービスのご利用が可能です
全表示
概要
目次
関連レポート

概要

蛋白尿治療薬の世界市場は2030年までに26億米ドルに達する見込み

蛋白尿治療薬の世界市場は、2023年に18億米ドルと推定され、分析期間2023-2030年にCAGR 5.2%で成長し、2030年には26億米ドルに達すると予測されます。アンジオテンシン変換酵素（ACE）阻害剤は、本レポートで分析したセグメントの1つであり、CAGRは7.8%を記録し、分析期間終了時には9億4,920万米ドルに達すると予測されます。アンジオテンシン受容体拮抗薬（arbs）セグメントの成長率は、分析期間中CAGR 5.0％と推定されます。

米国市場は5億220万米ドルと推定、中国はCAGR 9.0％で成長すると予測

米国の蛋白尿治療薬市場は、2023年に5億220万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億6,690万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と5.5%と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の蛋白尿治療薬市場- 主要動向と促進要因のまとめ

蛋白尿とは何か、なぜその治療が重要なのか？

尿中に異常な量のタンパク質が存在することを特徴とするタンパク尿は、腎臓障害の重要な指標であり、しばしば慢性腎臓病（CKD）の警告サインとして機能します。CKDは、糸球体として知られる腎臓のろ過装置が損傷し、血液中のタンパク質を保持できなくなり、尿中にタンパク質が漏れ出すことで発症します。未治療の蛋白尿は腎臓病の進行を早め、腎機能障害をさらに進行させ、透析や腎移植が必要になる可能性があります。蛋白尿は腎疾患のマーカーであるだけでなく、心血管イベントの危険因子でもあるため、その管理は患者のQOLに大きな影響を与える合併症を予防する上で極めて重要です。治療は通常、糖尿病や高血圧などの基礎疾患をコントロールすることに重点を置き、タンパク質の漏出を減らし、腎障害の進行を遅らせる治療法を用います。

誰が蛋白尿治療薬を必要としているのでしょうか？

蛋白尿治療薬は、慢性腎臓病、糖尿病、高血圧、糸球体腎炎と診断された患者にとって特に重要です。これらの治療薬は、蛋白漏出を引き起こす根本的なメカニズムに対処することにより、腎機能を保護し、重篤な合併症のリスクを軽減するため、不可欠です。アンジオテンシン変換酵素（ACE）阻害薬とアンジオテンシンII受容体拮抗薬（ARB）は、血圧を下げ、蛋白排泄を減少させるため、蛋白尿の管理によく処方されます。さらに、ナトリウム-グルコース共輸送体-2（SGLT2）阻害薬のような新しい薬剤クラス別は、蛋白尿を減少させるだけでなく、心血管への効果も期待されており、治療薬として重要な位置を占めています。蛋白尿治療の目標は、症状を管理するだけでなく、腎臓病の進行を遅らせたり、予防したりすることであり、これらの治療法は腎治療の要となっています。

蛋白尿治療薬の最新動向とイノベーションとは？

蛋白尿治療薬の分野では、より効果的で的を絞った治療の開発に焦点を当てた研究が進められており、大きな進歩が見られます。最も注目すべき動向のひとつは、エンドセリン受容体拮抗薬やミネラルコルチコイド受容体拮抗薬といった新規薬剤クラス別の研究であり、蛋白尿を減少させ、腎機能を保護する新たな作用機序を提供しています。さらに、従来のACE阻害薬やARBとSGLT2阻害薬やファインレノンなどの新薬を統合し、蛋白尿とそれに関連するリスクを包括的に管理することを目的とした併用療法への関心も高まっています。精密医療もこの分野に進出しており、治療効果を高め、副作用を最小限に抑えるために、遺伝子やバイオマーカーのプロファイルに基づいて治療法が調整されています。さらに、非侵襲的モニタリング技術の進歩により、蛋白尿レベルをより正確に評価できるようになり、より良い疾患管理とタイムリーな治療調整が可能となっています。こうした技術革新が蛋白尿治療薬の進化を促し、腎臓病患者の予後改善に希望をもたらしています。

蛋白尿治療薬市場の成長の促進要因は？

蛋白尿治療薬市場の成長は、慢性腎臓病および関連疾患の世界の有病率の増加を反映するいくつかの要因によって牽引されています。主な要因としては、糖尿病と高血圧の罹患率の上昇が挙げられ、これらはタンパク尿の発症に大きく寄与します。これらの病態が、特に高齢化した人口集団や新興市場でより広まるにつれて、効果的な蛋白尿治療薬に対する需要が高まると予想されます。薬剤開発の技術的進歩、特に新規治療クラスや併用療法の導入も、より効果的な治療選択肢を提供することで市場の成長を後押ししています。腎臓病の早期診断と早期管理への注目の高まりは、ヘルスケアプロバイダーが腎障害の進行を予防しようとしていることから、蛋白尿治療薬の採用をさらに加速させています。さらに、蛋白尿と心血管リスクとの関連性に対する認識の高まりは、腎臓と心血管両方の健康を管理する二重の利点を提供する治療に対する需要を促進しています。このような要因が、現在進行中の研究開発と相まって、蛋白尿治療薬市場の拡大に拍車をかけています。

調査対象企業の例（全49件）

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • Certa Therapeutics
  • Everest Medicines
  • Ionis Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Travere Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Walden Biosciences, Inc.
  • ZyVersa Therapeutics, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次

Product Code: MCP26787

Global Proteinuria Therapeutics Market to Reach US$2.6 Billion by 2030

The global market for Proteinuria Therapeutics estimated at US$1.8 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Angiotensin-converting Enzyme (ACE) Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$949.2 Million by the end of the analysis period. Growth in the Angiotensin Receptor Blockers (arbs) segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$502.2 Million While China is Forecast to Grow at 9.0% CAGR

The Proteinuria Therapeutics market in the U.S. is estimated at US$502.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$566.9 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Proteinuria Therapeutics Market - Key Trends and Drivers Summarized

What Is Proteinuria and Why Is Its Treatment So Critical?

Proteinuria, characterized by the presence of abnormal amounts of protein in the urine, is a key indicator of kidney damage and often serves as a warning sign for chronic kidney disease (CKD). The condition arises when the kidneys' filtering units, known as glomeruli, are damaged and cannot retain proteins in the bloodstream, leading to their leakage into the urine. Untreated proteinuria can accelerate the progression of kidney disease, leading to further renal dysfunction and potentially necessitating dialysis or kidney transplantation. Proteinuria is not only a marker of kidney disease but also a risk factor for cardiovascular events, making its management crucial for preventing complications that can significantly impact a patient's quality of life. Treatment typically focuses on controlling underlying conditions such as diabetes and hypertension, using therapies that reduce protein leakage and slow kidney damage progression.

Who Needs Proteinuria Therapeutics and Why Are They So Essential?

Proteinuria therapeutics are particularly vital for patients diagnosed with chronic kidney disease, diabetes, hypertension, and glomerulonephritis—conditions that often lead to or exacerbate proteinuria. These therapies are essential because they address the underlying mechanisms that cause protein leakage, thereby protecting kidney function and reducing the risk of severe complications. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are commonly prescribed to manage proteinuria, as they help lower blood pressure and reduce protein excretion. Additionally, newer classes of drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, have shown promise in not only reducing proteinuria but also providing cardiovascular benefits, making them an important addition to the therapeutic arsenal. The goal of proteinuria treatment is not only to manage symptoms but to delay or prevent the progression of kidney disease, making these therapies a cornerstone of renal care.

What Are the Latest Trends and Innovations in Proteinuria Therapeutics?

The field of proteinuria therapeutics has witnessed significant advancements, with ongoing research focused on developing more effective and targeted treatments. One of the most notable trends is the exploration of novel drug classes, such as endothelin receptor antagonists and mineralocorticoid receptor antagonists, which offer new mechanisms of action for reducing proteinuria and protecting kidney function. Additionally, there is growing interest in combination therapies that integrate traditional ACE inhibitors or ARBs with newer agents like SGLT2 inhibitors or finerenone, aiming to provide comprehensive management of proteinuria and its associated risks. Precision medicine is also making inroads in this field, with therapies being tailored based on genetic and biomarker profiles to enhance treatment efficacy and minimize adverse effects. Furthermore, advances in non-invasive monitoring technologies are enabling more accurate assessment of proteinuria levels, allowing for better disease management and timely therapeutic adjustments. These innovations are driving the evolution of proteinuria therapeutics, offering hope for improved outcomes for patients with kidney disease.

What Is Driving the Growth of the Proteinuria Therapeutics Market?

The growth in the proteinuria therapeutics market is driven by several factors that reflect the increasing prevalence of chronic kidney disease and related conditions globally. A primary driver is the rising incidence of diabetes and hypertension, which are major contributors to the development of proteinuria. As these conditions become more widespread, particularly in aging populations and emerging markets, the demand for effective proteinuria therapies is expected to rise. Technological advancements in drug development, particularly the introduction of novel therapeutic classes and combination therapies, are also propelling market growth by offering more effective treatment options. The increasing focus on early diagnosis and management of kidney disease is further accelerating the adoption of proteinuria therapeutics, as healthcare providers seek to prevent the progression of kidney damage. Additionally, the growing awareness of the link between proteinuria and cardiovascular risk is driving demand for treatments that offer dual benefits in managing both renal and cardiovascular health. These factors, coupled with ongoing research and development efforts, are fueling the expansion of the proteinuria therapeutics market.

Select Competitors (Total 49 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • Certa Therapeutics
  • Everest Medicines
  • Ionis Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Travere Therapeutics
  • Vertex Pharmaceuticals Inc.
  • Walden Biosciences, Inc.
  • ZyVersa Therapeutics, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Proteinuria Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Kidney Disease Propels Growth in Proteinuria Therapeutics Market
    • Increasing Incidence of Diabetes and Hypertension Drives Adoption of Proteinuria Therapies
    • Advancements in Drug Development Strengthen Business Case for Novel Proteinuria Treatments
    • Expanding Research in Nephrology Expands Addressable Market Opportunity for Proteinuria Therapeutics
    • Growing Focus on Cardiovascular Risk Management Generates Demand for Integrated Therapies
    • Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics Market
    • Shift Towards Personalized Medicine Expands Market Potential for Targeted Proteinuria Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Proteinuria Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Proteinuria Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Angiotensin-converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers (arbs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Angiotensin Receptor Blockers (arbs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Angiotensin Receptor Blockers (arbs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Dipeptidyl Peptidase (DPP) IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Aldosterone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Proteinuria Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Proteinuria Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Proteinuria Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Proteinuria Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Proteinuria Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Proteinuria Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Proteinuria Therapeutics by Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for Proteinuria Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (arbs), Dipeptidyl Peptidase (DPP) IV Inhibitors, Diuretics, Aldosterone Antagonists and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

蛋白尿治療薬の世界市場
発行日
発行
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報
英文 199 Pages
納期
即日から翌営業日

関連レポート

タンパク尿治療薬市場：薬剤クラス別、投与経路別、流通経路別、地域別
発行日
2026年01月13日

サンプル依頼リストに
追加しました

リストを確認する